Differential properties of human ACL and MCL stem cells may be responsible for their differential healing capacity
© Zhang et al; licensee BioMed Central Ltd. 2011
Received: 23 May 2011
Accepted: 2 June 2011
Published: 2 June 2011
The human anterior cruciate ligament (hACL) and medial collateral ligament (hMCL) of the knee joint are frequently injured, especially in athletic settings. It has been known that, while injuries to the MCL typically heal with conservative treatment, ACL injuries usually do not heal. As adult stem cells repair injured tissues through proliferation and differentiation, we hypothesized that the hACL and hMCL contain stem cells exhibiting unique properties that could be responsible for the differential healing capacity of the two ligaments.
To test the above hypothesis, we derived ligament stem cells from normal hACL and hMCL samples from the same adult donors using tissue culture techniques and characterized their properties using immunocytochemistry, RT-PCR, and flow cytometry.
We found that both hACL stem cells (hACL-SCs) and hMCL stem cells (hMCL-SCs) formed colonies in culture and expressed stem cell markers nucleostemin and stage-specific embryonic antigen-4 (SSEA-4). Moreover, both hACL-SCs and hMCL-SCs expressed CD surface markers for mesenchymal stem cells, including CD44 and CD90, but not those markers for vascular cells, CD31, CD34, CD45, and CD146. However, hACL-SCs differed from hMCL-SCs in that the size and number of hACL-SC colonies in culture were much smaller and grew more slowly than hMCL-SC colonies. Moreover, fewer hACL-SCs in cell colonies expressed stem cell markers STRO-1 and octamer-binding transcription factor-4 (Oct-4) than hMCL-SCs. Finally, hACL-SCs had less multi-differentiation potential than hMCL-SCs, evidenced by differing extents of adipogenesis, chondrogenesis, and osteogenesis in the respective induction media.
This study shows for the first time that hACL-SCs are intrinsically different from hMCL-SCs. We suggest that the differences in their properties contribute to the known disparity in healing capabilities between the two ligaments.
The human anterior cruciate ligament (hACL) and medial collateral ligament (hMCL) are two major ligaments that function to stabilize the knee joint. Because knee joints are subjected to large mechanical loads, particularly in athletic settings, both ligaments are frequently injured. It has been established that the injured hACL rarely heals, often requiring surgical reconstruction. As a result, patients with injured ACLs typically experience recurrent instability of the knee joint , which could lead to development of osteoarthritis . On the other hand, the injured hMCL typically heals with conservative, non-operative treatment [3, 4].
Several theories have been proposed as to why this difference in healing capability exists between the ACL and MCL. These include intra-articular versus extra-articular environments, different mechanical environments [5, 6], and differences in nitric oxide synthesis , vascular supply , and proliferative potential of fibroblasts [9, 10]. In recent years, however, the importance of adult stem cells (ASCs) in tissue healing has been noted [11–13]. ASCs are characterized in vitro by their remarkable abilities to proliferate extensively in an uncommitted state (self-renewal) and differentiate into cell types of various tissue lineages (multi-potential), including adipocytes, chondrocytes, and osteocytes. ASCs are responsible for repair and regeneration of injured tissues by proliferation and differentiation. Multipotent ASCs have been found in various types of tissues including bone marrow , adipose tissue [15, 16], umbilical cord , synovium , spinal cord , dental pulp , and periodontal ligaments . Recently, human, mouse, and rabbit tendons were found to contain stem cells, and these tendon stem cells (TSCs) exhibit the three universal characteristics of ASCs: clonogenicity, self-renewal, and multi-differentiation potential [22, 23]. Therefore, we inferred that hACL and hMCL also contain ASCs. Indeed, a previous study showed that cells derived from young rabbit ACLs and MCLs exhibit stem cell properties .
Because ASCs are responsible for repair and regeneration of injured tissues, and because injured ACLs and MCLs have differential healing capacities as noted above, we hypothesized in this study that both human ACLs and MCLs contain ASCs, but that they exhibit distinctive, ligament-specific properties. To test this hypothesis, we derived stem cells from normal human ACL and MCL samples from the same donors. We then characterized and compared the properties of the two types of ligament stem cells, denoted hACL-SCs and hMCL-SCs, respectively. Herein we report the findings of this study.
hACL and hMCL stem cell cultures
Human ACL and MCL samples
Trypsin was locally applied to each colony under microscopic visualization in order to detach stem cell colonies, and detached cells were collected and transferred to T25 flasks for further culture. The growth medium consists of Dulbecco's modified Eagle's medium (DMEM; Lonza, Walkersville, MD) supplemented with 20% fetal bovine serum (FBS; Atlanta Biologicals, Lawrenceville, GA), 100 μM 2-mercaptoethanol (Sigma-Aldrich, St Louis), 100 U/ml penicillin, and 100 μg/ml streptomycin (Atlanta Biologicals, Lawrenceville, GA). To measure the proliferative capacities of hACL-SCs and hMCL-SCs, we used population doubling time (PDT) as an index. Briefly, hACL-SCs or hMCL-SCs were seeded in 6-well plates at a density of 6 × 104/well and cultured with growth medium until confluence. The PDT is calculated by dividing the total culture time by the number of generations .
Expression of stem cell markers by hACL-SCs and hMCL-SCs
Immunocytochemistry was used to assay for expression of the following stem cell markers: nucleostemin, Oct-4, STRO-1, and SSEA-4. To perform immunostaining, hACL-SCs or hMCL-SCs were seeded in 12-well plates at a density of 3.5 × 104/well and cultured with growth medium for 3 days. The medium was then removed, and the cells were washed with PBS once. The stem cells were first fixed in 4% paraformaldehyde in phosphate-buffered saline (PBS) for 20 minutes. For nucleostemin and Oct-4 staining, this step was followed by washing with 0.1% Triton-X100 for 15 minutes. All cells were then blocked with 3% mouse serum for 1 hour. In the first antibody reaction, the stem cells were incubated with either mouse anti-human STRO-1 (1:400, Cat. #39-8401, Invitrogen, Carlsbas, CA), mouse anti-human SSEA-4 (1:400, Cat. #414000, Invitrogen, Carlsbas, CA), goat anti-human nucleostemin (1:350, Cat. # GT15050, Neuromics, Edina, MN), or rabbit anti-human Oct-3/4 (1:350, Cat. # sc-9081, Santa Cruz Biotechnology, Santa Cruz, CA) at room temperature for 2 hours. After washing the cells with PBS, cyanine 3 (Cy3)-conjugated goat anti-mouse immunoglobulin G (IgG) secondary antibody (1:500, Cat.# A10521, Invitrogen, Catlsbas, CA) was applied at room temperature for 1 hour to STRO-1 and SSEA-4 samples while Cy3-conjugated donkey anti-goat IgG secondary antibody (1:500, Cat.# AP180C, Millipore, Temecula, CA) was used for nucleostemin and Cy-3 conjugated goat anti-rabbit IgG antibody (1:400, Cat. # AP132C, Millipore, Temecula, CA) was used for Oct-3/4 samples at room temperature for 2 hours. The cells were also counterstained with Hoechst 33342 (Cat. # 33270; Sigma, St Louis).
In addition, stem cell surface markers CD31, CD44, CD90, CD34, CD45, and CD146 were stained in parallel by immunocytochemistry. Fixed cells were incubated with fluorescein isothiocyanate (FITC)- or Cy3- or phycoerythrin (PE)-conjugated mouse anti-human antibodies (1:400) for 1 hour. All steps were performed at room temperature. Unless otherwise noted, all antibodies were purchased from Chemicon International (Temecula, CA), BD Pharmingen (BD Biosciences; http://bdbiosciences.com), or Santa Cruz Biotechnology (Santa Cruz, CA). Fluorescent images of the stained cells were taken by a CCD camera on an inverted fluorescent microscope (Nikon eclipse, TE2000-U) using SPOT™ imaging software (Diagnostic Instruments, Inc., Sterling Heights, MI).
Multi-differentiation potentials of hACL-SCs and hMCL-SCs
The multi-differentiation potentials of hACL-SCs and hMCL-SCs were examined in vitro to determine whether they could undergo adipogenesis, chondrogenesis, and osteogenesis. Cells at passage 1 were seeded in a 6-well plate at a density of 2.4 × 105 cells/well in basic growth medium consisting of low glucose DMEM, 10% heat inactivated FBS, 100 U/ml penicillin, and 100 μg/ml streptomycin. After reaching confluence, cells for adipogenesis were cultured in adipogenic induction medium (Millipore, Cat. # SCR020) consisting of basic growth medium supplemented with 1 μM dexamethasone, 10 μg/ml insulin, 100 μM indomethacin, and 0.5 mM isobutylmethylxanthine (IBMX) for 21 days. Oil Red O assay was used to detect lipid droplets contained in the differentiated adipocytes.
For chondrogenesis, confluent stem cells were cultured in chondrogenic induction medium consisting of basic growth medium along with 40 μg/ml proline, 39 ng/ml dexamethasone, 10 ng/ml transforming growth factor beta 3 (TGF-β3), 50 μg/ml ascorbate 2-phosphate, 100 μg/ml sodium pyruvate, and 50 mg/ml ITS premix (BD, Cat. # 354350). After 21 days in culture, the glycosaminoglycans (GAG)-rich matrix produced by differentiated chondrocytes was stained using the Safranin O assay.
Finally, for osteogenic differentiation, stem cells were cultured in osteogenic induction medium consisting of basic growth medium with 0.1 μM dexamethasone, 0.2 mM ascorbic 2-phosphate, and 10 mM glycerol 2-phosphate for 21 days. The differentiated cells released calcium-rich deposits, which were stained by the Alizarin Red S assay. Cells cultured in basic growth medium for the same durations were used as a control.
Oil Red O assay
After discarding the medium, the cells were washed 3 times for 5 minutes each with PBS. The cells were then fixed in 4% paraformaldehyde for 40 minutes at room temperature. Subsequently, the cells were washed 3 times with PBS at 5 minute intervals and then with water twice for 5 minutes each. Finally, the cells were incubated with 0.36% Oil Red O solution (Millipore, Cat. # 90358) for 50 minutes, followed by washing 3 times with water.
Safranin O assay
The cells were fixed in ice-cold ethanol for 1 hour, rinsed with distilled water twice for 5 minutes each, and stained with Safranin O solution (Sigma, Cat. # HT904) for 30 minutes. The cells were then rinsed five times with distilled water.
Alizarin Red S assay
The cells cultured in osteogenic medium were fixed in chilled 70% ethanol for 1 hour, rinsed with distilled water for 5 minutes twice, and stained with Alizarin Red S solution (Millipore, Cat. # 2003999) for 30 minutes at room temperature. The cells then underwent five rinses with distilled water. Cells stained with the three assays were examined, and images were taken and analyzed on an inverted fluorescent microscope as noted earlier.
Semi-quantification of the extent of cell differentiation
Briefly, 12 views from each well were randomly chosen on a microscope with a magnification of 20×. Then, the areas of positive staining were identified manually and computed by SPOT IMAGING Software. Next, the proportion of positive staining was calculated by dividing the stained area by the view area. Twelve ratio values for each of three wells were averaged to obtain the percentage of positive staining, which represents the extent of cell differentiation in the respective induction medium.
Flow cytometry (FACS) analysis
The cell suspension (2.5 × 106 in 50 μl PBS) was incubated with 20 μl of the appropriate serum in a round-bottomed tube at 4°C for 30 minutes. Subsequently, 2 μl of primary antibody (0.2 mg/ml stock solution) was added and incubated at 4°C for 1 hour. The cells were then washed three times with 2% FBS-PBS and reacted with 1 μl of secondary antibody (1 mg/ml stock solution) at 4°C for 1 hour. Afterwards the cells were washed twice with PBS and then fixed with 0.5 ml of 1% paraformaldehyde. FACS analysis was performed with BD LSR II Flow Cytometer (BD Biosciences, http://www.bdbiosciences.com).
Gene expression analysis by RT-PCR
Primers used for RT-PCR analysis
5'-GCT GTT ATG GGT GAA ACT CTG-3'
5'-CTC GGA CGT AGA GGT GGA ATA-3'
Risbud MV, et al. 2007
5'-GAG ATT TCT CTG TAT GGC ACC-3'
5'-CTG CAA ATG AGA CAC TTT CTC-3'
Risbud MV, et al. 2007
5'-ATC TGA AGA AGG AGA GCG AG-3'
5'-TCA GAA GTC TCC AGA GCT TG-3'
Risbud MV, et al. 2007
5'-TTT CCC AGG TCA AGA TGG TC-3'
5'-TCA CCT GGT TTT CCA CCT TC-3'
Risbud MV, et al. 2007
5'-ACG ACA ACC GCA CCA TGG T-3'
5'-CTG TAA TCT GAC TCT GTC CT-3'
Risbud MV, et al. 2007
5'-TGG AGC TTC AGA AGC TCA ACA CCA-3'
5'-ATC TCG TTG TCT GAG TAC CAG TCC-3'
Risbud MV, et al. 2007
5'-GTG GTG GTA CGG GAA ATC AC-3'
5'-TAG CCA GGT TCG AGA ATC CA-3'
Huangfu D, et al. 2008
5'-GAA GCT AAA GTG GAT TCA GGA GTA-3'
5'-TAA GCA GGG GAC CAT TAC A-3'
Rada T, et al. 2010
5'-GGG CTG CTT TTA ACT CTG GT-3'
5'-TGG CAG GTT TTT CTA GAC GG-3'
Risbud MV, et al. 2007
For each experimental condition, at least three replicates were performed. The results presented in the figures are representative of these (mean ± SD, n = 3 to 6). Two-tailed student t-test was used for statistical analysis. A P-value less than 0.05 was considered to be significantly different.
Clonogenicity and growth capacity of hACL-SCs and hMCL-SCs
Stem cell marker expression of hACL-SCs and hMCL-SCs
FACS results of stem cell marker expression (%)
20.1 ± 1.2
23.8 ± 5.8
89.1 ± 0.9
62.4 ± 6.0
48.7 ± 5.7
94.6 ± 1.3
Self-renewal of hACL-SCs and hMCL-SCs
Both hACL-SCs and hMCL-SCs were able to undergo self-renewal, indicated by the maintenance of a cobblestone shape after repetitive passage and expression of stem cell markers nucleostemin and SSEA-4.
Multidifferentiation potential of hACL-SCs and hMCL-SCs
Adult stem cells were isolated and identified from hACLs and hMCLs. We showed that these hACL-SCs and hMCL-SCs exhibit characteristic stem cell properties, including clonogenicity, self-renewal, and multi-potency. Furthermore, both populations expressed stem cell markers nucleostemin, SSEA-4, STRO-1, and Oct-4 as well as several CD markers (CD44 and CD90) for mesenchymal stem cells (MSCs), but not those for endothelial cells, hematopoietic stem cells, leukocytes, or pericytes (CD31, CD34, CD45, and CD146). However, it was found that a smaller proportion of hACL-SCs expressed STRO-1, Oct-4, and CD44 compared to hMCL-SCs. hACL-SCs also grew about 50% slower and formed smaller and fewer colonies than hMCL-SCs. Moreover, there was a marked difference in long-term self-renewal capability between the two types of stem cells: hACL-SCs became differentiated after only five passages and two months in culture, whereas hMCL-SCs maintained a nearly undifferentiated state even after 13 passages and the same culture time. Taken together, these results show that hACL-SCs and hMCL-SCs are ligament specific stem cells that possess intrinsically different stem cell properties.
Nucleostemin, SSEA-4, STRO-1, and Oct-4 are four well established stem cell markers used to confirm the stem cell identity of hACL-SCs and hMCL-SCs in this study. Nucleostemin is a nucleolar protein believed to act via p53 [25, 26] and to be expressed by stem cells and cancer cells but not terminally differentiated cells [26, 27]. Thus, high levels of nucleostemin expression by hACL-SCs and hMCL-SCs in this study were indicative of proliferating, self-renewing populations of ASCs. Like nucleostemin, Oct-4 is also a nuclear protein expressed in embryonic stem cells and carcinoma cell lines but not in differentiated cells . Oct-4 expression is lost during the process of differentiation, and downregulation of Oct-4 is thought to directly induce stem cell differentiation [29–31].
SSEA-4 is a member of the stage specific antigen family first identified as a marker that disappeared from human teratocarcinoma cells as they differentiated [32, 33], which has since been recognized as a marker of human embryonic stem cells  and mesenchymal stem cells  as well. STRO-1 is a cell surface antigen found on bone marrow mononuclear cells  capable of differentiating down osteogenic [37, 38], chondrogenic, and adipogenic lines . In addition, STRO-1 is expressed in human periodontal ligament stem cells .
In addition to the stem cell markers above, we examined the expression of CD surface markers on hACL-SCs and hMCL-SCs. Both ACL-SCs and MCL-SCs expressed CD44 and CD90 (albeit the former exhibited a less extent than the latter). Neither of the two types of ligament stem cells expressed CD31, CD34, CD45, or CD146. CD44 is a common MSC antigen [41, 42] and is used as a marker for bone marrow stem cells (BMSCs) . CD90 is a fibroblast marker that has also been found on undifferentiated human embryonic stem cells , and human MSCs are consistently positive for both CD44 and CD90 [44–46]. Endothelial cell marker CD31 , hematopoietic stem cell marker CD34 , pericyte marker CD146 , and leukocyte marker CD45  were expressed by neither hACL-SCs nor hMCL-SCs. These results provide additional evidence that hACL-SCs and hMCL-SCs are ASCs of mesenchymal origin.
A recent study by Cheng et al. looked into the possibility of populations of stem cells existing in human ACLs . It was shown that cells isolated from the ACL are clonogenic with multidifferentiation potential and express surface markers similar to MSCs, including CD73, CD90, and CD105. The hACL-SCs isolated in our study displayed similar characteristics as the ligament stem cells from Cheng et al.'s study in terms of clonogenicity, multipotency, and expression of stem cell markers CD44 and CD90, but not CD34 or CD45. However, unlike this study, the ACL samples used by Cheng et al. may not be normal as they were collected from patients who had undergone total knee arthroplasty.
Another study, in which ligament cells were derived from young rabbits, found that the chondrogenic potential of 'ligament-derived cells' was greater for ACL cells than MCL cells . However, their study used a mixed cell population rather than isolated stem cells as this study did. Finally, tissue specific stem cells, such as hACL-SCs and hMCL-SCs, have been found in various tissues, including bone marrow , the periodontal ligament , and human, mouse, and rabbit patellar tendons [22, 23], which are similar to extra-articular ligaments. In addition, rat flexor tendons were found to contain stem cells . Our group has also shown that stem cells from rabbit patellar and Achilles tendons express nucleostemin, Oct-4, and SSEA-4 . The same stem cell markers were found to be expressed on both hACL-SCs and hMCL-SCs in this study.
While both hACL-SCs and hMCL-SCs were shown to be ASCs, differences were also observed with regard to their clonogenicity, self-renewal capacity, and differentiation potential. We previously also found that stem cells derived from rabbit patellar and Achilles tendons exhibit marked differences in colony formation and cell proliferation rate . Differences in gene profiles have also been noted between MSCs derived from human intra-articular (synovium, meniscus, and ACL) and extra-articular sources (adipose, muscle, and bone) . In addition, previous studies showed that ACL fibroblasts proliferate more slowly than their MCL counterparts [9, 53]. These above studies, however, differ from this study in that they used mixed cultures; in other words, the cell population could include both stem cells and residential adult cells (for example, ACL fibroblasts). Nevertheless, the finding in this study that hACL-SCs proliferate much more slowly than hMCL-SCs (Figure 2) is largely consistent with conclusions of the above studies.
It is well recognized that injured ACLs have a low healing capacity, whereas injured MCLs display a high healing capacity [54–56]. Given that ASCs are the body's natural reservoir for replenishing pools of specialized cells that have been damaged in tissue injury, we suggest that the differential characteristics of hACL-SCs and hMCL-SCs found in this study may also contribute to their respective ligaments' differential healing capacities. Specifically, our data seem to indicate that hACL-SCs lose their 'stemness' earlier than hMCL-SCs. This may contribute to non-healing of injured ACLs as the hACL-SCs may have lost their ability to self-renew during the healing process; as a result, few cells will be available for repair of the injured ACLs. On the other hand, because of their superior capability of self-renewal, hMCL-SCs can continuously supply cells to effectively repair injured MCLs.
Besides the inherent lower stem cell capacity of hACL-SCs, blood flow, an 'external' factor, is known to be lower in the ACL than in the MCL in both intact and injured states. As a result, fewer nutrients will be available to hACL-SCs compared to hMCL-SCs. Therefore, again a smaller number of hACL-SCs and their progeny cells will be produced compared to hMCL-SCs.
The finding that the hACL contains ASCs may enable one to devise a new tissue engineering approach for repair of injured hACLs. This could be done by using small portions of ligaments to isolate and expand hACL-SCs in vitro and then implanting the cells into the injured ACL. On the other hand, while the injured MCL heals spontaneously, the quality of the healed tissue is still inferior with scar formation . This is true even with implantation of natural scaffolding materials [58, 59]. Therefore, hMCL-SCs may also be used as a source for cellular-based therapies to restore the structure and function of the injured MCL.
Several comments are now in place regarding the proper interpretation of the results of this study. First, we used local application of trypsin to isolate stem cell colonies in cultures. Such a technique may be subject to contamination of a small number of ligament fibroblasts; in other words, the stem cell populations used in this study may not be pure. Second, there is an apparent difference in the results of stem cell marker expression between immunocytochemistry (Figure 3) and FACS analysis (Table 3). The difference may be caused by the different passages of cells and the number of donors used in the two different methods. For immunostaining we used hACL-SCs and hMCL-SCs at passage 1 from a 26 year old donor, but for FACS analysis, passages 2 to 3 from six donors were used and the results were represented by mean ± SD. Third, hACL-SCs and hMCL-SCs were found to express low levels of non-tenocyte related genes, including PPARγ, LPL, Sox-9, collagen II, and Runx-2, even without differentiation induction media. There are two possible reasons for this. While the ligaments used in our experiments were limited at grade 0 (normal), the donors might have slight degenerative changes in their ACL and MCL ligaments. Additionally, there is a possibility that a small population of stem cells that somehow had differentiated towards non-fibroblasts was present in cultures.
We show in this study that while both hACL-SCs and hMCL-SCs exhibited clonogenicity, self-renewal, and multi-differentiation potential, the three universal characteristics of ASCs, hACL-SCs differed from hMCL-SCs in that hACL-SCs expressed a much lower level of STRO-1 and Oct-4, two stem cell marker genes. Moreover, compared to hMCL-SCs, hACL-SCs exhibited a lower capacity for colony formation, slower proliferation, a shorter period of self-renewal capability, and a lower extent of multidifferentiation potential. As ASCs are responsible for repair and regeneration of injured tissues, we suggest that the differences in the properties of the two ligaments' stem cells may contribute to the differential healing capacities of injured ACLs and MCLs observed clinically.
adult stem cells
bone marrow stem cells
fluorescence activated cell scanning
glyceradehyde 3-phosphate dehydrogenase
human anterior cruciate ligament
human medial collateral ligament
mesenchymal stem cells
octamer-binding transcription factor-4
peroxisome proliferator-activated receptor gamma
stage-specific embryonic antigen-4
transforming growth factor beta 3
tendon stem cells.
We gratefully acknowledge funding support from NIH grants AR049921, AR049921S1, and AR049921S2, and the Albert B. Ferguson, Jr., MD Orthopedic Fund of The Pittsburgh Foundation (JHW).
- Frank CB, Jackson DW: The science of reconstruction of the anterior cruciate ligament. J Bone Joint Surg Am. 1997, 79: 1556-1576.PubMedGoogle Scholar
- Barrack RL, Bruckner JD, Kneisl J, Inman WS, Alexander AH: The outcome of nonoperatively treated complete tears of the anterior cruciate ligament in active young adults. Clin Orthop Relat Res. 1990, 259: 192-199.PubMedGoogle Scholar
- Woo SL, Niyibizi C, Matyas J, Kavalkovich K, Weaver-Green C, Fox RJ: Medial collateral knee ligament healing. Combined medial collateral and anterior cruciate ligament injuries studied in rabbits. Acta Orthop Scand. 1997, 68: 142-148. 10.3109/17453679709003997.View ArticlePubMedGoogle Scholar
- Chen H, Tang Y, Li S, Shen Y, Liu X, Zhong C: Biologic characteristics of fibroblast cells cultured from the knee ligaments. Chin J Traumatol. 2002, 5: 92-96.PubMedGoogle Scholar
- Bedi A, Kawamura S, Ying L, Rodeo SA: Differences in tendon graft healing between the intra-articular and extra-articular ends of a bone tunnel. HSS J. 2009, 5: 51-57. 10.1007/s11420-008-9096-1.View ArticlePubMedGoogle Scholar
- Beynnon BD, Fleming BC, Labovitch R, Parsons B: Chronic anterior cruciate ligament deficiency is associated with increased anterior translation of the tibia during the transition from non-weightbearing to weightbearing. J Orthop Res. 2002, 20: 332-337. 10.1016/S0736-0266(01)00115-2.View ArticlePubMedGoogle Scholar
- Cao M, Stefanovic-Racic M, Georgescu HI, Fu FH, Evans CH: Does nitric oxide help explain the differential healing capacity of the anterior cruciate, posterior cruciate, and medial collateral ligaments?. Am J Sports Med. 2000, 28: 176-182.PubMedGoogle Scholar
- Bray RC, Leonard CA, Salo PT: Correlation of healing capacity with vascular response in the anterior cruciate and medial collateral ligaments of the rabbit. J Orthop Res. 2003, 21: 1118-1123. 10.1016/S0736-0266(03)00078-0.View ArticlePubMedGoogle Scholar
- Amiel D, Nagineni CN, Choi SH, Lee J: Intrinsic properties of ACL and MCL cells and their responses to growth factors. Med Sci Sports Exerc. 1995, 27: 844-851.View ArticlePubMedGoogle Scholar
- Yoshida M, Fujii K: Differences in cellular properties and responses to growth factors between human ACL and MCL cells. J Orthop Sci. 1999, 4: 293-298. 10.1007/s007760050106.View ArticlePubMedGoogle Scholar
- Gao J, Caplan AI: Mesenchymal stem cells and tissue engineering for orthopaedic surgery. Chir Organi Mov. 2003, 88: 305-316.PubMedGoogle Scholar
- Young RG, Butler DL, Weber W, Caplan AI, Gordon SL, Fink DJ: Use of mesenchymal stem cells in a collagen matrix for Achilles tendon repair. J Orthop Res. 1998, 16: 406-413. 10.1002/jor.1100160403.View ArticlePubMedGoogle Scholar
- Bruder SP, Fink DJ, Caplan AI: Mesenchymal stem cells in bone development, bone repair, and skeletal regeneration therapy. J Cell Biochem. 1994, 56: 283-294.View ArticlePubMedGoogle Scholar
- Caplan AI: The mesengenic process. Clin Plast Surg. 1994, 21: 429-435.PubMedGoogle Scholar
- Zuk PA, Zhu M, Mizuno H, Huang J, Futrell JW, Katz AJ, Benhaim P, Lorenz HP, Hedrick MH: Multilineage cells from human adipose tissue: implications for cell-based therapies. Tissue Eng. 2001, 7: 211-228. 10.1089/107632701300062859.View ArticlePubMedGoogle Scholar
- Zuk PA, Zhu M, Ashjian P, De Ugarte DA, Huang JI, Mizuno H, Alfonso ZC, Fraser JK, Benhaim P, Hedrick MH: Human adipose tissue is a source of multipotent stem cells. Mol Biol Cell. 2002, 13: 4279-4295. 10.1091/mbc.E02-02-0105.View ArticlePubMedPubMed CentralGoogle Scholar
- Erices A, Conget P, Minguell JJ: Mesenchymal progenitor cells in human umbilical cord blood. Br J Haematol. 2000, 109: 235-242. 10.1046/j.1365-2141.2000.01986.x.View ArticlePubMedGoogle Scholar
- De Bari C, Dell'Accio F, Tylzanowski P, Luyten FP: Multipotent mesenchymal stem cells from adult human synovial membrane. Arthritis Rheum. 2001, 44: 1928-1942. 10.1002/1529-0131(200108)44:8<1928::AID-ART331>3.0.CO;2-P.View ArticlePubMedGoogle Scholar
- Risbud MV, Guttapalli A, Tsai TT, Lee JY, Danielson KG, Vaccaro AR, Albert TJ, Gazit Z, Gazit D, Shapiro IM: Evidence for skeletal progenitor cells in the degenerate human intervertebral disc. Spine. 2007, 32: 2537-2544. 10.1097/BRS.0b013e318158dea6.View ArticlePubMedGoogle Scholar
- Gronthos S, Mankani M, Brahim J, Robey PG, Shi S: Postnatal human dental pulp stem cells (DPSCs) in vitro and in vivo. Proc Natl Acad Sci USA. 2000, 97: 13625-13630. 10.1073/pnas.240309797.View ArticlePubMedPubMed CentralGoogle Scholar
- Gronthos S, Mrozik K, Shi S, Bartold PM: Ovine periodontal ligament stem cells: isolation, characterization, and differentiation potential. Calcif Tissue Int. 2006, 79: 310-317. 10.1007/s00223-006-0040-4.View ArticlePubMedGoogle Scholar
- Bi Y, Ehirchiou D, Kilts TM, Inkson CA, Embree MC, Sonoyama W, Li L, Leet AI, Seo BM, Zhang L, Shi S, Young MF: Identification of tendon stem/progenitor cells and the role of the extracellular matrix in their niche. Nat Med. 2007, 13: 1219-1227. 10.1038/nm1630.View ArticlePubMedGoogle Scholar
- Zhang J, Wang JH: Characterization of differential properties of rabbit tendon stem cells and tenocytes. BMC Musculoskelet Disord. 2010, 11: 10-10.1186/1471-2474-11-10.View ArticlePubMedPubMed CentralGoogle Scholar
- Furumatsu T, Hachioji M, Saiga K, Takata N, Yokoyama Y, Ozaki T: Anterior cruciate ligament-derived cells have high chondrogenic potential. Biochem Biophys Res Commun. 2010, 391: 1142-1147. 10.1016/j.bbrc.2009.12.044.View ArticlePubMedGoogle Scholar
- Normile D: Cell proliferation. Common control for cancer, stem cells. Science. 2002, 298: 1869-10.1126/science.298.5600.1869.View ArticlePubMedGoogle Scholar
- Tsai RY, McKay RD: A nucleolar mechanism controlling cell proliferation in stem cells and cancer cells. Genes Dev. 2002, 16: 2991-3003. 10.1101/gad.55671.View ArticlePubMedPubMed CentralGoogle Scholar
- Kafienah W, Mistry S, Williams C, Hollander AP: Nucleostemin is a marker of proliferating stromal stem cells in adult human bone marrow. Stem Cells. 2006, 24: 1113-1120. 10.1634/stemcells.2005-0416.View ArticlePubMedGoogle Scholar
- Pesce M, Gross MK, Scholer HR: In line with our ancestors: Oct-4 and the mammalian germ.[erratum appears in Bioessays 1998 Dec;20:1056]. Bioessays. 1998, 20: 722-732. 10.1002/(SICI)1521-1878(199809)20:9<722::AID-BIES5>3.0.CO;2-I.View ArticlePubMedGoogle Scholar
- Niwa H, Toyooka Y, Shimosato D, Strumpf D, Takahashi K, Yagi R, Rossant J: Interaction between Oct3/4 and Cdx2 determines trophectoderm differentiation.[see comment]. Cell. 2005, 123: 917-929. 10.1016/j.cell.2005.08.040.View ArticlePubMedGoogle Scholar
- Hay DC, Sutherland L, Clark J, Burdon T: Oct-4 knockdown induces similar patterns of endoderm and trophoblast differentiation markers in human and mouse embryonic stem cells. Stem Cells. 2004, 22: 225-235. 10.1634/stemcells.22-2-225.View ArticlePubMedGoogle Scholar
- Reubinoff BE, Pera MF, Fong CY, Trounson A, Bongso A: Embryonic stem cell lines from human blastocysts: somatic differentiation in vitro. Nat Biotechnol. 2000, 18: 399-404. 10.1038/74447.View ArticlePubMedGoogle Scholar
- Kannagi R, Cochran NA, Ishigami F, Hakomori S, Andrews PW, Knowles BB, Solter D: Stage-specific embryonic antigens (SSEA-3 and -4) are epitopes of a unique globo-series ganglioside isolated from human teratocarcinoma cells. EMBO J. 1983, 2: 2355-2361.PubMedPubMed CentralGoogle Scholar
- Brimble SN, Sherrer ES, Uhl EW, Wang E, Kelly S, Merrill AH, Robins AJ, Schulz TC: The cell surface glycosphingolipids SSEA-3 and SSEA-4 are not essential for human ESC pluripotency. Stem Cells. 2007, 25: 54-62. 10.1634/stemcells.2006-0232.View ArticlePubMedGoogle Scholar
- Yu J, Thomson JA: Pluripotent stem cell lines. Genes Dev. 2008, 22: 1987-1997. 10.1101/gad.1689808.View ArticlePubMedPubMed CentralGoogle Scholar
- Gang EJ, Bosnakovski D, Figueiredo CA, Visser JW, Perlingeiro RC: SSEA-4 identifies mesenchymal stem cells from bone marrow. Blood. 2007, 109: 1743-1751. 10.1182/blood-2005-11-010504.View ArticlePubMedGoogle Scholar
- Simmons PJ, Torok-Storb B: Identification of stromal cell precursors in human bone marrow by a novel monoclonal antibody, STRO-1. Blood. 1991, 78: 55-62.PubMedGoogle Scholar
- Gronthos S, Graves SE, Ohta S, Simmons PJ: The STRO-1+ fraction of adult human bone marrow contains the osteogenic precursors. Blood. 1994, 84: 4164-4173.PubMedGoogle Scholar
- Stewart K, Walsh S, Screen J, Jefferiss CM, Chainey J, Jordan GR, Beresford JN: Further characterization of cells expressing STRO-1 in cultures of adult human bone marrow stromal cells. J Bone Miner Res. 1999, 14: 1345-1356. 10.1359/jbmr.19126.96.36.1995.View ArticlePubMedGoogle Scholar
- Dennis JE, Carbillet JP, Caplan AI, Charbord P: The STRO-1+ marrow cell population is multipotential. Cells Tissues Organs. 2002, 170: 73-82. 10.1159/000046182.View ArticlePubMedGoogle Scholar
- Seo BM, Miura M, Gronthos S, Bartold PM, Batouli S, Brahim J, Young M, Robey PG, Wang CY, Shi S: Investigation of multipotent postnatal stem cells from human periodontal ligament. Lancet. 2004, 364: 149-155. 10.1016/S0140-6736(04)16627-0.View ArticlePubMedGoogle Scholar
- Kolf CM, Cho E, Tuan RS: Mesenchymal stromal cells. Biology of adult mesenchymal stem cells: regulation of niche, self-renewal and differentiation. Arthritis Res & Ther. 2007, 9: 204-10.1186/ar2116.View ArticleGoogle Scholar
- Segawa Y, Muneta T, Makino H, Nimura A, Mochizuki T, Ju YJ, Ezura Y, Umezawa A, Sekiya I: Mesenchymal stem cells derived from synovium, meniscus, anterior cruciate ligament, and articular chondrocytes share similar gene expression profiles. J Orthop Res. 2009, 27: 435-441. 10.1002/jor.20786.View ArticlePubMedGoogle Scholar
- Kaufman DS, Hanson ET, Lewis RL, Auerbach R, Thomson JA: Hematopoietic colony-forming cells derived from human embryonic stem cells. Proc Natl Acad Sci USA. 2001, 98: 10716-10721. 10.1073/pnas.191362598.View ArticlePubMedPubMed CentralGoogle Scholar
- Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA, Simonetti DW, Craig S, Marshak DR: Multilineage potential of adult human mesenchymal stem cells. Science. 1999, 284: 143-147. 10.1126/science.284.5411.143.View ArticlePubMedGoogle Scholar
- Wexler SA, Donaldson C, Denning-Kendall P, Rice C, Bradley B, Hows JM: Adult bone marrow is a rich source of human mesenchymal 'stem' cells but umbilical cord and mobilized adult blood are not. Br J Haematol. 2003, 121: 368-374. 10.1046/j.1365-2141.2003.04284.x.View ArticlePubMedGoogle Scholar
- Phinney DG, Prockop DJ: Concise review: mesenchymal stem/multipotent stromal cells: the state of transdifferentiation and modes of tissue repair--current views. Stem Cells. 2007, 25: 2896-2902. 10.1634/stemcells.2007-0637.View ArticlePubMedGoogle Scholar
- DeLisser HM, Newman PJ, Albelda SM: Molecular and functional aspects of PECAM-1/CD31. Immunol Today. 1994, 15: 490-495. 10.1016/0167-5699(94)90195-3.View ArticlePubMedGoogle Scholar
- Simmons DL, Satterthwaite AB, Tenen DG, Seed B: Molecular cloning of a cDNA encoding CD34, a sialomucin of human hematopoietic stem cells. J Immunol. 1992, 148: 267-271.PubMedGoogle Scholar
- Salomon D, Ayalon O, Patel-King R, Hynes RO, Geiger B: Extrajunctional distribution of N-cadherin in cultured human endothelial cells. J Cell Sci. 1992, 102: 7-17.PubMedGoogle Scholar
- Fischer EH, Charbonneau H, Tonks NK: Protein tyrosine phosphatases: a diverse family of intracellular and transmembrane enzymes. Science. 1991, 253: 401-406. 10.1126/science.1650499.View ArticlePubMedGoogle Scholar
- Cheng MT, Yang HW, Chen TH, Lee OK: Isolation and characterization of multipotent stem cells from human cruciate ligaments. Cell Prolif. 2009, 42: 448-460. 10.1111/j.1365-2184.2009.00611.x.View ArticlePubMedGoogle Scholar
- Rui YF, Lui PP, Li G, Fu SC, Lee YW, Chan KM: Isolation and Characterization of Multipotent Rat Tendon-Derived Stem Cells. Tissue Eng Part A. 2010, 16: 1549-1558. 10.1089/ten.tea.2009.0529.View ArticlePubMedGoogle Scholar
- Nagineni CN, Amiel D, Green MH, Berchuck M, Akeson WH: Characterization of the intrinsic properties of the anterior cruciate and medial collateral ligament cells: an in vitro cell culture study. J Orthop Res. 1992, 10: 465-475. 10.1002/jor.1100100402.View ArticlePubMedGoogle Scholar
- Indelicato PA: Non-operative treatment of complete tears of the medial collateral ligament of the knee. J Bone Joint Surg Am. 1983, 65: 323-329.PubMedGoogle Scholar
- Kannus P: Long-term results of conservatively treated medial collateral ligament injuries of the knee joint. Clin Orthop Relat Res. 1988, 226: 103-112.PubMedGoogle Scholar
- Reider B, Sathy MR, Talkington J, Blyznak N, Kollias S: Treatment of isolated medial collateral ligament injuries in athletes with early functional rehabilitation. A five-year follow-up study. Am J Sports Med. 1994, 22: 470-477. 10.1177/036354659402200406.View ArticlePubMedGoogle Scholar
- Frank C, Amiel D, Woo SL, Akeson W: Normal ligament properties and ligament healing. Clin Orthop Relat Res. 1985, 196: 15-25.PubMedGoogle Scholar
- Liang R, Woo SL, Takakura Y, Moon DK, Jia F, Abramowitch SD: Long-term effects of porcine small intestine submucosa on the healing of medial collateral ligament: a functional tissue engineering study. J Orthop Res. 2006, 24: 811-819. 10.1002/jor.20080.View ArticlePubMedGoogle Scholar
- Musahl V, Abramowitch SD, Gilbert TW, Tsuda E, Wang JH, Badylak SF, Woo SL: The use of porcine small intestinal submucosa to enhance the healing of the medial collateral ligament--a functional tissue engineering study in rabbits. J Orthop Res. 2004, 22: 214-220. 10.1016/S0736-0266(03)00163-3.View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1741-7015/9/68/prepub